Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 6565-year-old woman comes to the clinic for a routine follow-up. 55 years ago, a dual-energy x-ray absorptiometry (DEXA) scan revealed a T-score of −2.7-2.7 at the lumbar spine and −2.6-2.6 at the femoral neck. At that time, she was diagnosed with osteoporosis and was prescribed oral alendronate, along with daily calcium and vitamin D supplementation. She has been fully compliant with her regimen and has not experienced any clinical fractures. She does not smoke or consume alcohol, and she takes no other prescription medications.

Today, a repeat DEXA scan demonstrates a T-score of −1.9-1.9 at the lumbar spine and −2.0-2.0 at the femoral neck. A Fracture Risk Assessment Tool (FRAX) calculation indicates a low 1010-year probability of major osteoporotic and hip fractures. The patient inquires about the necessity of continuing her current osteoporosis pharmacotherapy.

Which of the following is the most appropriate next step in the management of this patient's bone health?

  1. A
    Continue oral alendronate for an additional 5 years
  2. Discontinue oral alendronate and repeat the DEXA scan in 2 to 3 yearsCevap
  3. C
    Switch oral alendronate to subcutaneous denosumab
  4. D
    Switch oral alendronate to subcutaneous teriparatide
  5. E
    Continue oral alendronate and add oral raloxifene

Cevap

Discontinue oral alendronate and repeat the DEXA scan in 2 to 3 years
The correct answer is to discontinue oral alendronate and repeat the DEXA scan in 2 to 3 years. This patient has completed 5 years of oral bisphosphonate therapy and currently has a low risk for fractures (current T-score > −2.5-2.5, no prior clinical fractures, and a low FRAX score). Because bisphosphonates bind strongly to bone hydroxyapatite and are released slowly over time, their antiresorptive effects persist for years after discontinuation. Prolonged use of bisphosphonates (typically > 5 years for oral agents) is associated with rare but severe adverse effects, specifically atypical femur fractures and osteonecrosis of the jaw. Therefore, current clinical guidelines recommend a 'drug holiday' for low-risk patients after 5 years of oral therapy. During this period, patients should continue daily calcium and vitamin D supplementation and undergo periodic DEXA monitoring every 2 to 4 years to ensure bone density remains stable.

Adım Adım Çözüm

1
Evaluate the patient's current fracture risk based on longitudinal data.
The patient has no history of fractures, a current T-score of -1.9 (osteopenia, which is > -2.5), and a low FRAX score.
Determining current fracture risk is required to decide whether to continue or pause osteoporosis therapy after the initial 5-year treatment course.
2
Apply the guidelines for bisphosphonate duration and drug holidays.
The patient meets all criteria for a bisphosphonate drug holiday.
Oral bisphosphonates accumulate in the bone matrix and provide persistent antiresorptive effects long after discontinuation, allowing for safe pauses in low-risk patients.
3
Select the most appropriate clinical intervention.
Discontinue alendronate and monitor with serial DEXA scans.
Continuing therapy beyond 5 years in low-risk patients increases the risk of rare adverse events (like atypical femur fractures) without adding significant fracture protection.

Anahtar Kavram

Patients who have completed 5 years of oral bisphosphonate therapy and have a low risk of fracture (T-score > -2.5 and no history of fractures) should be offered a drug holiday to minimize the risk of rare adverse effects.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru